2nd National Veterinary Advisory Council (NVAC) held at Bionote

The Korean Veterinary Association held 2nd National Veterinary Advisory Council (NVAC) at Bionote, Inc., on April 26th, 2022. The NVAC is an official advisory body within the Veterinary Society, providing advice to the government on the prevention of malignant livestock diseases such as FMD, ASF and major zoonotic diseases, while also serving to establish an official veterinary medical system.    Key figures at NVAC 2022 includes: Chairman Yong-Ho Park (Seoul National University Veterinary College), ▲ Jong-Gu Kang (Biotoxtech), ▲ Jong-Kil Kang (Chunghyeon General Veterinary Hospital), ▲ Gon-Seop Kim (Gyeongsang National University Veterinary College), ▲ Woo-Joo Kim (Korea University Guro Hospital), ▲ Young-Soo Ryu (Konkuk University Veterinary College) , ▲Seungwon Seo (Boehringer Ingelheim Veterinary Medicine), ▲Sangcheol Shin (Solgent), ▲Chunggeun Yoon (Asia Veterinary Hospital), ▲Soodu Lee (Ministry of Food and Drug Safety), ▲Poongkyu Lee (Knowhere bio), ▲Youngsik Cho (Bionote). For this year's council meeting, Professor Kim Woo-Joo, Department of Infectious Diseases at the Korea University Guro Hospital, discussed the current status of the COVID-19 pandemic, development of vaccines, changes due to the emergence of mutants, and future prospects and countermeasures, under the theme of 'COVID-19 Pandemic: Current Status and Prospects'. Bionote is the No. 1 manufacturer for veterinary diagnostic reagents in Korea. For its post pandemic growth engine,  Bionote will be focusing on expanding its business sector via molecular diagnostic analyzer Vcheck M, biochemistry analyzer Vcheck C, and bio-contents business.

• 2022.04.26
• Hits : 3,826

Excellent performance verification of Vcheck Canine NT-proBNP (SCI journal)

A paper on the analytical validation of Vcheck Canine NT-proBNP (BIONOTE) has been published in the international journal, Veterinary Clinical Pathology (Science Citation Index, Impact factor 1.18).Paper: Analytical validation of a novel point-of-care immunoassay for canine N-terminal pro-brain natriuretic peptide analysis (Vet Clin Pathol. 2022;00:1–10.) See the attached document for the summary and click here for the full paper (open access).   This study aimed to analytically validate a Vcheck NT-proBNP assay according to American Society of Veterinary Clinical Pathology (ASVCP) and Clinical Laboratory Improvement Amendments (CLIA) specifications.   Precision Imprecision was considered acceptable with a coefficient of variation ranging from 9% at 4000 pmol/L to 20% at 600 pmol/L.   Accuracy Comparison of the Vcheck assay with the Cardiopet NT-proBNP assay revealed an excellent correlation with minimal bias (y=0.9x+37, R2=0.9) when preanalytical factors were controlled.   Preanalytical error Significant degradation of NT-proBNP occurred when current methods were used at refrigerated (average loss of 20%) and room temperatures (loss of at least 50%), which could change diagnostic and prognostic decision-making.   Interferents (analytical specificity) Spiking samples across the linear range of the assay with 35 mg/dL hemoglobin and 1000 mg/dL Intralipid did not reveal a statistically significant difference.   Reference intervals Age-partitioned reference intervals (95%) have upper reference limits of 750 pmol/L and 1280 pmol/L for 36 juvenile and 125 adult dogs, respectively.     According to this study, the Vcheck assay provides analytically acceptable results. Onsite testing can minimize variability related to preanalytical error and provide clinically useful contemporaneous results.   Also, the author emphasized that samples should be centrifuged immediately and analyzed within 2 hours of collection, due to significant degradation of NT-proBNP.   Results of this study demonstrate that the Vcheck NT-proBNP assay is a valid point-of-care cardiac biomarker using the canine serum.   Vcheck Canine NT-proBNP can be quantitatively measured using a fluorescent immunoassay analyzer (Vcheck) in a short time (15 minutes) and can be tested using a small amount of sample (serum 100 µl). Learn more

• 2022.04.07
• Hits : 10,433

BioNote USA, attending the Western Veterinary Conference which is the largest Veterinary Science Society in the United States

Bionote USA attended the Western Veterinary Conference to be held March 6th to March 9th, 2022 at the Mandalay Bay Convention Center in Las Vegas, Nevada.WVC’s Annual Conference is one of the largest, most influential gatherings of veterinary professionals in the world. Bionote USA communicated with veterinary workers and vets who attended the conference through participation in the booth about how Vcheck could develop and help veterinary medicine.   On this day, renowned Dr. Rozanski sponsored by Bionote, spoke about the role of NT-proBNP in clinical decision making and the benefits of point-of-care testing. NT-proBNP is correlated with heart size and systolic function, suggesting that the concentrations can be used to detect dogs with early disease. In addition, Vcheck Canine NT-proBNP is an in vitro diagnostic test kit for the quantitative measurement of NT-proBNP concentration in canine serum. This test kit precisely quantifies the degree of elevation in NT-proBNP levels in dogs. The ability to distinguish cardiac from non-cardiac causes of respiratory signs is important for further decisions on diagnostics and therapy. NT-proBNP allows distinguishing cardiac from respiratory disease in dogs with dyspnea. Also, this marker helps to detect dogs with Myxomatous Mitral Valve Degeneration (MMVD), which is the most common heart disease in dogs. In dogs with stable Congestive Heart Failure (CHF) due to MMVD, NT-proBNP is of value in monitoring the effectiveness of medical treatment for CHF. In large breeds, Dilated Cardiomyopathy (DCM) is the most common cause of heart disease. Annual screening tests are recommended to determine if DCM is present even if dogs at elevated risk are healthy. The measurement of NT-proBNP increases the diagnostic accuracy with Holter monitoring (91% accuracy). Vcheck Canine NT-proBNP: The one-step test procedure is easy to follow and provides fast results within 15 minutes using serum samples from dogs. Bionote USA completed the 2022 Western Veterinary Conference, and in addition, Bionote KOREA and Bionote CHINA also plan to hold various external activities and conferences. 

• 2022.03.14
• Hits : 4,044